A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pazopanib (Primary) ; Temsirolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TemPa
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2018 Primary endpoint has not been met. (Progression Free Survival (PFS)) as per result presented at the 2018 Genitourinary Cancers Symposium
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium